Published in Dig Dis Sci on January 01, 2006
Case report of an intra-abdominal desmoid tumour presenting with bowel perforation. Mcgill J Med (2007) 1.04
A multidisciplinary approach to desmoid tumors. When intra-abdominal fibromatosis degenerates into an abscess, which is the right treatment? Int J Surg Case Rep (2013) 0.78
Mesenteric desmoid tumour masquerading as a fat-containing cystic mass. Br J Radiol (2010) 0.75
Mesenteric desmoid tumour presenting with recurrent abdominal abscess and duodenal fistula: A case report and review of literature. Int J Surg Case Rep (2017) 0.75
Intraabdominal abscess caused by actinomycosis in a patient with mesenteric fibromatosis of the small intestine: report of a case. Surg Today (2012) 0.75
Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoid tumors: A comparative review of 22 articles. Cancer (2000) 4.05
The occurrence of desmoids in patients with familial polyposis coli. Br J Surg (1970) 2.21
Desmoid tumours complicating familial adenomatous polyposis. Br J Surg (1999) 1.85
Surgery, desmoid tumors, and familial adenomatous polyposis: case report and literature review. Am J Gastroenterol (1996) 1.06
Abscess formation in desmoid tumors of Gardner's syndrome and percutaneous drainage: a report of three cases. Cardiovasc Intervent Radiol (1995) 0.95
Large intra-abdominal desmoid tumors in a patient with familial adenomatosis coli: their rapid growth detected by computerized tomography. Am J Gastroenterol (1993) 0.76
Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol (2010) 2.50
Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease. Aliment Pharmacol Ther (2013) 2.22
An evaluation of emergency sclerotherapy of varices in randomized trials: looking the needle in the eye. Endoscopy (2006) 2.22
An appraisal of the histopathological assessment of liver fibrosis. Gut (2006) 1.87
Systematic review: The model for end-stage liver disease--should it replace Child-Pugh's classification for assessing prognosis in cirrhosis? Aliment Pharmacol Ther (2005) 1.86
Multiple systems organ failure from organophosphate poisoning. J Toxicol Clin Toxicol (1995) 1.79
Risk factors for target non-attainment during empirical treatment with β-lactam antibiotics in critically ill patients. Intensive Care Med (2014) 1.68
Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology (2000) 1.66
Early prediction of successful alpha-interferon therapy of chronic hepatitis C by core-IgM antibodies to hepatitis C virus. J Hepatol (1994) 1.40
New insights into the coagulopathy of liver disease and liver transplantation. World J Gastroenterol (2006) 1.17
Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with and without cavernous transformation. Aliment Pharmacol Ther (2006) 1.15
Malignant gastrointestinal melanomas of unknown origin: should it be considered primary? World J Gastroenterol (2007) 1.14
Thrombotic risk factors and extent of liver fibrosis in chronic viral hepatitis. Gut (2003) 1.08
Diabetes mellitus in chronic hepatitis B and C: prevalence and potential association with the extent of liver fibrosis. J Viral Hepat (2006) 1.07
Over-expression of p53 nuclear oncoprotein in colorectal adenomas. Int J Cancer (1992) 1.07
Serum apoptotic caspase activity as a marker of severity in HBeAg-negative chronic hepatitis B virus infection. Gut (2007) 1.05
Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis (2010) 1.03
High genetic barrier nucleos(t)ide analogue(s) for prophylaxis from hepatitis B virus recurrence after liver transplantation: a systematic review. Am J Transplant (2012) 1.02
Clinical predictors of poor outcomes among patients with nonvariceal upper gastrointestinal bleeding in Europe. Aliment Pharmacol Ther (2011) 1.01
Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy. Ann Oncol (2006) 1.00
Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia. Eur Respir J (2010) 1.00
Natural course of treated and untreated chronic HCV infection: results of the nationwide Hepnet.Greece cohort study. Aliment Pharmacol Ther (2009) 0.99
Future trends of HCV-related cirrhosis and hepatocellular carcinoma under the currently available treatments. J Viral Hepat (2005) 0.98
Veno occlusive disease: update on clinical management. World J Gastroenterol (2007) 0.98
Hepatitis E virus infection in a cohort of patients with acute non-A, non-B hepatitis. J Hepatol (1995) 0.98
Biochemical and virological outcome of patients with chronic hepatitis C treated with interferon alfa-2b for 6 or 12 months: a 4-year follow-up of 211 patients. Hepatology (1997) 0.96
Review article: novel therapeutic options for chronic hepatitis C. Aliment Pharmacol Ther (2008) 0.96
Serum hepcidin levels are related to the severity of liver histological lesions in chronic hepatitis C. J Viral Hepat (2010) 0.94
The effects of glycosaminoglycans on coagulation: a thromboelastographic study. Blood Coagul Fibrinolysis (2007) 0.92
Fulminant hepatic failure as a presenting paraneoplastic manifestation of Hodgkin's disease. Eur J Gastroenterol Hepatol (1999) 0.91
Gliclazide-induced acute hepatitis. Eur J Gastroenterol Hepatol (2000) 0.89
Longitudinal changes in serum HBV DNA levels and predictors of progression during the natural course of HBeAg-negative chronic hepatitis B virus infection. J Viral Hepat (2008) 0.89
Reversal of liver failure in sickle cell vaso-occlusive crisis. Am J Med Sci (1996) 0.88
Metabolic syndrome is associated with severe fibrosis in chronic viral hepatitis and non-alcoholic steatohepatitis. Aliment Pharmacol Ther (2007) 0.87
Heparin-like effect in liver disease and liver transplantation. Clin Liver Dis (2009) 0.86
Hepatic steatosis in chronic hepatitis B develops due to host metabolic factors: a comparative approach with genotype 1 chronic hepatitis C. Dig Liver Dis (2007) 0.84
The Bcl-2/Bax system and apoptosis in ulcerative colitis. Hepatogastroenterology (2007) 0.83
Seasonal variation in exacerbations of ulcerative colitis. Hepatogastroenterology (1997) 0.83
A partially overlapping treatment course with lamivudine and interferon in hepatitis B e antigen-negative chronic hepatitis B. Aliment Pharmacol Ther (2006) 0.83
Factors associated with severity and disease progression in chronic hepatitis C. Hepatogastroenterology (1999) 0.83
Terbinafine-induced cholestatic liver disease. J Hepatol (1996) 0.83
Histopathology of chronic hepatitis C in relation to epidemiological factors. J Hepatol (1996) 0.83
Type I Gaucher disease with severe skeletal destruction, extraosseous extension, and monoclonal gammopathy. Am J Hematol (2004) 0.82
Analytical and clinical sensitivity of the Procleix Ultrio HIV-1/HCV/HBV assay in samples with a low viral load. Vox Sang (2007) 0.82
Granulocyte colony-stimulating factor improves function of neutrophils from patients with acute liver failure. Eur J Gastroenterol Hepatol (2000) 0.82
Impact of interferon-alpha therapy on liver fibrosis progression in patients with HBeAg-negative chronic hepatitis B. J Viral Hepat (2005) 0.82
Differential diagnosis of acute HBsAg positive hepatitis using IgM anti-HBc by a rapid, fully automated microparticle enzyme immunoassay. J Hepatol (1997) 0.81
Recurrent hepatitis C after liver transplantation. J Med Virol (2000) 0.81
Serum HCV RNA levels and HCV genotype do not affect insulin resistance in nondiabetic patients with chronic hepatitis C: a multicentre study. Aliment Pharmacol Ther (2009) 0.80
Chronic hepatitis C and no response to antiviral therapy: potential current and future therapeutic options. J Viral Hepat (2004) 0.80
The transjugular route: the key hole to the liver world. Dig Liver Dis (2006) 0.79
Prevalence of glucose intolerance in patients with chronic hepatitis B or C: a prospective case-control study. J Viral Hepat (2009) 0.78
Predictors of the early development of advanced metachronous colon adenomas. Hepatogastroenterology (1997) 0.78
Combined hepatocellular-cholangiocarcinoma presented with massive pulmonary embolism. Hepatogastroenterology (2001) 0.78
p53 protein accumulation and colonic adenoma recurrence. Eur J Gastroenterol Hepatol (1999) 0.78
Towards a better liver transplant allocation system. Liver Transpl (2007) 0.78
Comparative efficacy of a high or low dose of interferon alpha 2b in chronic hepatitis C: a randomized controlled trial. Am J Gastroenterol (1996) 0.77
Prophylactic and therapeutic use of recombinant activated factor VII in patients with cirrhosis and coagulation impairment. Dig Liver Dis (2006) 0.76
Core variability does not affect response to interferon alpha in HBeAg negative chronic hepatitis B. J Hepatol (1998) 0.76
Acute pancreatitis associated with Salmonella enteritidis. Am J Gastroenterol (2001) 0.76
Are upper gastrointestinal symptoms associated with exacerbations of COPD? Int J Clin Pract (2008) 0.76
Bloodstream infections in ICU with increased resistance: epidemiology and outcomes. Minerva Anestesiol (2014) 0.76
Post-infantile giant cell hepatitis associated with autoimmune hepatitis and polyarteritis nodosa. Scand J Gastroenterol (2002) 0.76
Relief of biliary obstruction due to portal vein cavernoma using a transjugular intrahepatic portosystemic shunt (TIPS) without the need for long-term stenting. Endoscopy (2006) 0.76
The usefulness of transient elastography in the assessment of patients with HBeAg-negative chronic hepatitis B virus infection. J Viral Hepat (2013) 0.76
Laparoscopic fenestration of multiple giant biliary mucinous cystadenomas of the liver. World J Gastroenterol (2008) 0.76
Letter: ulcerative colitis in patients transplanted for primary sclerosing cholangitis. Aliment Pharmacol Ther (2012) 0.75
Late abdominal wall inflammatory mass mimicking drain site recurrence after rectal cancer surgery. Hippokratia (2012) 0.75
Letter: renal tubular dysfunction during nucleotide analogue therapy in chronic hepatitis B. Aliment Pharmacol Ther (2012) 0.75
Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with and without underlying cirrhosis. Cardiovasc Intervent Radiol (2007) 0.75
Sclerosing lymphocytic lobulitis in the male breast. J Clin Pathol (1996) 0.75
Long-term outcome of chronic hepatitis C treated with interferon. Ital J Gastroenterol Hepatol (1999) 0.75
Acute delta hepatitis in Greek parenteral drug abusers. Prog Clin Biol Res (1993) 0.75
Retroperitoneal synovial sarcoma: a clinicopathological study of 6 cases. J BUON (2008) 0.75
Systemic absorption of 5-aminosalicylic acid in patients with inactive ulcerative colitis treated with olsalazine and mesalazine. Eur J Gastroenterol Hepatol (1996) 0.75
Erratum to: Risk factors for target non-attainment during empirical treatment with β-lactam antibiotics in critically ill patients. Intensive Care Med (2015) 0.75
Prevalence of antibodies to hepatitis C virus in Greek patients with chronic liver disease. J Hepatol (1994) 0.75
Prevalence of antibodies to hepatitis C virus in Greek patients with chronic liver disease. J Hepatol (1994) 0.75
Hepatobiliary and pancreatic: spontaneous splenorenal shunts in portal hypertension. J Gastroenterol Hepatol (2006) 0.75
Paroxysmal atrial tachycardia associated with prednisolone administration. J Postgrad Med (2010) 0.75
Phytocontact dermatitis caused by artichoke: an exceptionally rare case. Clin Exp Dermatol (2009) 0.75
Painful pustular eruption in the groin and the scrotum induced by erlotinib. J Eur Acad Dermatol Venereol (2008) 0.75
Indefinite dysplasia in ulcerative colitis has little clinical significance and is not associated with p53 protein accumulation. Am J Gastroenterol (1998) 0.75
Management of recurrent hepatitis C after liver transplantation. J Viral Hepat (2001) 0.75
The impact of using biodiesel/marine gas oil blends on exhaust emissions from a stationary diesel engine. J Environ Sci Health A Tox Hazard Subst Environ Eng (2008) 0.75
Amineptine induced liver injury. Report of two cases and brief review of the literature. Hepatogastroenterology (1997) 0.75